Factors associated with long-term antibody response after COVID-19 vaccination in patients treated with systemic treatment for solid tumors
Open Access
Abstract
No abstract availableFunding Information
- ZonMw
This publication has 5 references indexed in Scilit:
- Immunogenicity after second and third mRNA-1273 vaccination doses in patients receiving chemotherapy, immunotherapy, or both for solid tumoursThe Lancet Oncology, 2022
- Immune responses following third COVID-19 vaccination are reduced in patients with hematological malignancies compared to patients with solid cancerCancer Cell, 2022
- Antibody responses following third mRNA COVID-19 vaccination in patients with cancer and potential timing of a fourth vaccinationCancer Cell, 2022
- mRNA-1273 COVID-19 vaccination in patients receiving chemotherapy, immunotherapy, or chemoimmunotherapy for solid tumours: a prospective, multicentre, non-inferiority trialThe Lancet Oncology, 2021
- Reduced humoral immune response after BNT162b2 coronavirus disease 2019 messenger RNA vaccination in cancer patients under antineoplastic treatmentESMO Open, 2021